GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Galderma Group AG (OTCPK:GALDY) » Definitions » Construction In Progress

GALDY (Galderma Group AG) Construction In Progress : $213 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Galderma Group AG Construction In Progress?

Galderma Group AG's quarterly construction in progress declined from Dec. 2023 ($188 Mil) to Jun. 2024 ($0 Mil) but then increased from Jun. 2024 ($0 Mil) to Dec. 2024 ($213 Mil).

Galderma Group AG's annual construction in progress increased from . 20 ($0 Mil) to Dec. 2023 ($188 Mil) and increased from Dec. 2023 ($188 Mil) to Dec. 2024 ($213 Mil).

Galderma Group AG Construction In Progress Historical Data

The historical data trend for Galderma Group AG's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galderma Group AG Construction In Progress Chart

Galderma Group AG Annual Data
Trend Dec23 Dec24
Construction In Progress
188.00 213.00

Galderma Group AG Semi-Annual Data
Jun23 Dec23 Jun24 Dec24
Construction In Progress - 188.00 - 213.00

Galderma Group AG Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Galderma Group AG Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Galderma Group AG (OTCPK:GALDY) » Definitions » Construction In Progress
Comparable Companies
XSWX:SDZ XSWX:PPGN XSWX:SFZN XSWX:CURN ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN NSE:DIVISLAB HKSE:03692 XTAE:TEVA SHSE:688506 BOM:500087 TSE:4507 SZSE:000538 UTHR NSE:TORNTPHARM BOM:543904 BOM:500124
Traded in Other Exchanges
GDERF:USA GALDz:UK PY30:Germany GALD:Switzerland
Address
Zahlerweg 10, Zug, CHE, 6300
Website
https://www.galderma.com
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a standalone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 45% of net sales from the US and employs around 6,600 people.